Fifty-three children — the majority of ApproaCH’s 84-participant enrollment — were aged five or older at baseline, and that subgroup is now where navepegritide‘s two-year signal looks sharpest. At Week 52, TransCon CNP produced an annualized growth velocity of 5.84 cm/year (observed mean) versus 3.88 cm/year on placebo, a difference of nearly two centimeters per year that held its statistical footing well past the threshold of chance (p<0.0001). That magnitude matters because older children with achondroplasia have less residual growth window — extracting a durable velocity gain from a population already past the peak plasticity years is the harder clinical test, and navepegritide passed it.
The two-year architecture of ApproaCH is worth dissecting. The first 52 weeks were randomized and placebo-controlled; the second 52 were an open-label extension in which placebo crossovers joined the active arm. By Week 104, the continuous-treatment group showed a CDC-based height Z-score improvement of +0.58 from baseline, while crossover participants reached +0.36 — a gap that reflects the cost of a lost year of treatment. That crossover lag is not a minor footnote. It quantifies, in real patient data, what delayed initiation takes from a child’s growth trajectory and will be a powerful argument in conversations about early diagnosis and rapid access post-approval.
The safety read at two years remains clean in ways that matter mechanically. No symptomatic hypotension, no acceleration of bone age, and injection site reactions that were both infrequent and uniformly mild. Bone age acceleration is the shadow concern with any growth-promoting agent — the worry that you borrow height now and repay it in closed epiphyses later. Its absence through 104 weeks in the older subgroup, where that risk would theoretically concentrate, strengthens the physiological case that CNP-pathway stimulation is working through the right mechanism rather than through a blunt anabolic shortcut.
Navepegritide already holds FDA approval as YUVIWEL, granted in February 2026, and the EMA decision is expected in Q4 2026. The number to watch now is the crossover cohort’s Week 104 velocity: if it converges fully toward the continuous-treatment arm’s 5.71 cm/year, Ascendis has a durable catch-up argument; if it plateaus short of that mark, delayed start becomes a permanent deficit — and that asymmetry will define the urgency of every diagnosis-to-prescription conversation in European markets before year-end.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
